Table 5. Cox proportional hazard regression model for overall survival.
| Univariate | Multivariate† | |||
| crude HR (95% CI) | P-value | adjusted HR (95% CI) | P-value | |
| Group | ||||
| Basiliximab | 1.08 (0.68–1.72) | 0.733 | 0.58 (0.27–1.21) | 0.146 |
| Steroid | 1.00 (reference) | – | 1.00 (reference) | – |
| Gender | ||||
| Female | 1.00 (reference) | – | 1.00 (reference) | – |
| Male | 0.98 (0.52–1.87) | 0.961 | 0.89 (0.46–1.72) | 0.723 |
| Age (y) | ||||
| <50 | 1.00 (reference) | – | 1.00 (reference) | – |
| ≥50 | 0.71 (0.45–1.12) | 0.140 | 0.64 (0.40–1.02) | 0.059 |
| AFP1 | ||||
| <200 | 1.00 (reference) | – | ||
| ≥200 | 1.54 (0.97–2.45) | 0.067 | ||
| Transplant year | ||||
| 2003–2005 | 0.86 (0.54–1.37) | 0.516 | 0.57 (0.27–1.18) | 0.130 |
| 2006–2009 | 1.00 (reference) | – | 1.00 (reference) | – |
| Child–Pugh score2 | ||||
| 5–6 | 1.00 (reference) | – | ||
| 7–9 | 0.72 (0.44–1.17) | 0.180 | ||
| 10–15 | 0.91 (0.43–1.89) | 0.792 | ||
| Diabetes mellitus | ||||
| No | 1.00 (reference) | – | ||
| Yes | 0.94 (0.41–2.16) | 0.879 | ||
| HBV | ||||
| No | 1.00 (reference) | – | ||
| Yes | 0.47 (0.25–0.88) | 0.019 | ||
| Cirrhosis | ||||
| No | 1.00 (reference) | – | ||
| Yes | 0.44 (0.24–0.82) | 0.010 | ||
| HCC | ||||
| Primary liver cancer | 1.00 (reference) | – | ||
| Recurrent hepatocellular carcinoma | 1.38 (0.63–3.03) | 0.420 | ||
| No. of tumor | ||||
| <2 | 1.00 (reference) | – | ||
| ≥2 | 1.29 (0.82–2.02) | 0.278 | ||
| Diameter of largest tumor (cm) | ||||
| <5 | 1.00 (reference) | – | ||
| ≥5 | 2.35 (1.49–3.71) | 0.0002 | ||
| TNM tumor staging for HCC, n (%) | ||||
| Stage I | 1.00 (reference) | – | 1.00 (reference) | – |
| Stage II | 1.84 (0.85–4.01) | 0.122 | 1.50 (0.67–3.38) | 0.327 |
| Stage III+ | 5.54 (2.69–11.42) | <0.0001 | 3.08 (1.28–7.42) | 0.012 |
| Milan Criteria2, n (%) | ||||
| Within Milan | 0.21 (0.11–0.38) | <0.0001 | 0.35 (0.17–0.73) | 0.005 |
| Beyond Milan | 1.00 (reference) | – | 1.00 (reference) | – |
| UCSF Criteria1, n (%) | ||||
| Within UCSF | 0.22 (0.13–0.38) | <0.0001 | ||
| Beyond UCSF | 1.00 (reference) | – | ||
| Preoperative antiviral therapy, n (%) | ||||
| No | 1.00 (reference) | – | ||
| Yes | 1.14 (0.69–1.88) | 0.616 | ||
1
n = 173;
2
n = 177.
†
In the multivariate model, data of 177 subjects were included.
AFP = alpha-fetoprotein; CI = confidence interval; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; HR = hazard ratio; UCSF = University of California San Francisco.